One of the most vibrant areas of HIV research these days is the search for new, more convenient ways to use antiretroviral medicines (ARVs) to prevent HIV infection. Elri Voigt rounds up the HIV pre-exposure prophylaxis (PrEP) research presented at the recent International AIDS Society Conference, including a biodegradable antiretroviral implant.
The treatment of drug-resistant forms of tuberculosis has been transformed over the last decade with treatment becoming more effective, safer, and treatment duration in many cases dropping to under a year. Even so, treatment can still come with serious side effects and for some, it can still last over a year and a half. In a finding that may help further reduce side effects, new research has found that the dosage of a key drug can be lowered without compromising how well it works. Tiyese Jeranji and Marcus Low report.
